• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.395 -0.025 (-1.76%)
Delayed Quote Updated: 3:15 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,158,193
Open 1.420
Bid (Size) 1.390 (3,100)
Ask (Size) 1.400 (6,900)
Prev. Close 1.420
Today's Range 1.380 - 1.465
52wk Range 1.175 - 2.580
Shares Outstanding 52,346,231
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
October 26, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
October 05, 2026
From Autolus Therapeutics plc
Via GlobeNewswire

Performance

52-Week Range 45.9% below 52-week high
1.395
1.1852W Low 2.5852W High
1 Week 15.5% below 1-week high
1.391W Low 1.651W High

Autolus Therapeutics plc - American Depositary Shares (AUTL) traded between $1.18 and $2.58 over the past 52 weeks and last traded at $1.40, 45.9% below its 52-week high. Over the past week it ranged between $1.39 and $1.65.

Past 12 Months
-10.0%
-23.8%
-23.4%
-11.1%
-25.4%
-10.6%
1W -$0.16
1M -$0.44
3M -$0.43
6M -$0.18
YTD -$0.48
1Y -$0.17

AUTL was -10.6% over the past year, -11.1% over six months, -25.4% year to date, -10.0% in the last week.

12 Months vs Market
AUTL
-10.6%
DIA
+9.2%
SPY
+10.3%
QQQ
+8.3%
IWM
+14.1%

Over the past 12 months AUTL returned -10.6% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.3%, QQQ (Nasdaq 100) +8.3% and IWM (Russell 2000) +14.1%.

Volume & Liquidity 0.93× 3-mo avg
Today 2,158,193 3-mo avg 2.3M
1W
2.4M
1M
2.0M
3M
2.3M
6M
1.8M
YTD
1.8M
1Y
2.0M

AUTL most recently traded 2,158,193 shares against a 3-month average daily volume of 2.3M.

More News

Read More
News headline image
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
September 09, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus (AUTL) Q2 2026 Earnings Call Transcript ↗
August 18, 2026
Via The Motley Fool
Topics Earnings
Autolus Therapeutics (NASDAQ:AUTL) Posts Inline Q1 Results with First Positive Gross Margin, but Full-Year Guidance Slightly Below Consensus ↗
May 14, 2026
Via Chartmill
News headline image
Autolus Therapeutics Q2 Earnings Call Highlights ↗
August 11, 2026
Via MarketBeat
Topics Earnings
News headline image
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
August 11, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
August 03, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
Top stock movements in today's session. ↗
August 03, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
August 03, 2026
Via Chartmill
News headline image
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
August 03, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in Upcoming Investor Conference
June 25, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Receives Prix Galien UK Award
June 12, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in Upcoming Investor Conferences
May 27, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
May 21, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus (AUTL) Q1 2026 Earnings Transcript ↗
May 18, 2026
Via The Motley Fool
News headline image
Autolus Therapeutics Q1 Earnings Call Highlights ↗
May 14, 2026
Via MarketBeat
Topics Earnings
News headline image
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 14, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
May 05, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
April 29, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
April 22, 2026
Via Investor Brand Network
Topics Intellectual Property
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
April 22, 2026
Via Investor Brand Network
News headline image
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
April 22, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 21, 2026
From Autolus Therapeutics plc
Via GlobeNewswire

Frequently Asked Questions

Is Autolus Therapeutics plc - American Depositary Shares publicly traded?
Yes, Autolus Therapeutics plc - American Depositary Shares is publicly traded.
What exchange does Autolus Therapeutics plc - American Depositary Shares trade on?
Autolus Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Autolus Therapeutics plc - American Depositary Shares?
The ticker symbol for Autolus Therapeutics plc - American Depositary Shares is AUTL on the Nasdaq Stock Market
What is the current price of Autolus Therapeutics plc - American Depositary Shares?
The current price of Autolus Therapeutics plc - American Depositary Shares is 1.395
When was Autolus Therapeutics plc - American Depositary Shares last traded?
The last trade of Autolus Therapeutics plc - American Depositary Shares was at 11/03/26 03:15 PM ET
What is the market capitalization of Autolus Therapeutics plc - American Depositary Shares?
The market capitalization of Autolus Therapeutics plc - American Depositary Shares is 73.02M
How many shares of Autolus Therapeutics plc - American Depositary Shares are outstanding?
Autolus Therapeutics plc - American Depositary Shares has 73M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap